The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes

Journal of Drug Targeting

Volumn 23, Issue 6, 2015, Pages 506-518

  Benter, Ibrahim F ^a,b   Sarkhou, Fatima ^a   Al Khaldi, Abeer T ^a   Chandrasekhar, Bindu ^a   Attur, Sreeja ^a   Dhaunsi, Gursev S ^a   Yousif, Mariam H M ^a   Akhtar, Saghir ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b EASTERN MEDITERRANEAN UNIVERSITY   (Turkey)

Author keywords

Diabetes; drug repurposing; tyrosine kinase inhibitor; vascular complications; vascular reactivity; vascular smooth muscle cells

Indexed keywords

CELL PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN ROCK1; PROTEIN ROCK2; PROTEIN TYROSINE KINASE; RHO KINASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL REACTIVITY; BODY WEIGHT; CHEMICAL INDUSTRY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MESENTERY BLOOD FLOW; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; VASCULAR DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DRUG EFFECTS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROCEDURES; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; HYPERGLYCEMIA; MALE; MOLECULAR TARGETED THERAPY; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84938574466     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2015.1057150     Document Type: Article

References (46)

1. Gray SP, Jandeleit-Dahm K. The pathobiology of diabetic vascular complications-cardiovascular and kidney disease. J Mol Med (Berl) 2014; 92: 441-52
2. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013; 93: 137-88
3. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107: 1058-70
4. EDIC Study. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. J Am Med Assoc 2003; 290: 2159-67
5. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 2009; 15: 1298-306
6. Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13: 1349-58
7. Romeo G, Liu WH, Asnaghi V, et al. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 2002; 51: 2241-8
8. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014; 79: 34-74
9. Akhtar S, Benter IF. The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. BioImpacts 2013; 3: 5-9
10. Matrougui K. Diabetes and microvascular pathophysiology: role of epidermal growth factor receptor tyrosine kinase. Diabetes Metab Res Rev 2010; 26: 13-16
11. Benter IF, Yousif MH, Griffiths SM, et al. Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. Br J Pharmacol 2005; 145: 829-36
12. Benter IF, Yousif MH, Hollins AJ, et al. Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase. J Vasc Res 2005; 42: 284-91
13. Yousif MH, Benter IF, Akhtar S. The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery. Auton Autacoid Pharmacol 2005; 25: 69-78
14. Akhtar S, Yousif MH, Dhaunsi GS, et al. Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br J Pharmacol 2012; 165: 1390-400
15. Benter IF, Benboubetra M, Hollins AJ, et al. Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature. Vasc Pharmacol 2009; 51: 236-45
16. Belmadani S, Palen DI, Gonzalez-Villalobos RA, et al. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 2008; 57: 1629-37
17. Palen DI, Matrougui K. Role of elevated EGFR phosphorylation in the induction of structural remodeling and altered mechanical properties of resistance artery from type 2 diabetic mice. Diabetes Metab Res Rev 2008; 24: 651-6
18. Akhtar S, Yousif MH, Dhaunsi GS, et al. Activation of ErbB2 and downstream signaling via rho kinases and ERK1/2 contributes to diabetes-induced vascular dysfunction. PLoS One 2013; 8: e67813
19. Ono N, Yamazaki T, Nakanishi Y, et al. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer Sci 2012; 103: 342-9
20. Leow CC, Chesebrough J, Coffman KT, et al. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol Cancer Ther 2009; 8: 2131-41
21. Hollins AJ, Omidi Y, Benter IF, Akhtar S. Toxicogenomics of drug delivery systems: exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J Drug Target 2007; 15: 83-8
22. Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 2011; 32: 167-73
23. Surma M, Wei L, Shi J. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol 2011; 7: 657-71
24. Oellerich MF, Potente M. FOXOs and sirtuins in vascular growth, maintenance, and aging. Circ Res 2012; 110: 1238-51
25. Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 2011; 1813: 1938-45
26. Portbury AL, Ronnebaum SM, Zungu M, et al. Back to your heart: ubiquitin proteasome system-regulated signal transduction. J Mol Cell Cardiol 2012; 52: 526-37
27. Maiese K, Shang YC, Chong ZZ, Hou J. Diabetes mellitus: channeling care through cellular discovery. Curr Neurovasc Res 2010; 7: 59-64
28. Akhtar S, Yousif MH, Chandrasekhar B, Benter, IF. Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. PLoS One 2012; 7: e39066
29. Arunachalam G, Samuel SM, Marei I, et al. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol 2014; 171: 523-35
30. Mortuza R, Chen S, Feng B, et al. High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway. PLoS One 2013; 8: e54514
31. Xu F, Wang Y, Cui W, et al. Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-B pathway. Int J Endocrinol 2014; 2014: 289327
32. Mohamed SA, Radtke A, Saraei R, et al. Locally different endothelial nitric oxide synthase protein levels in ascending aortic aneurysms of bicuspid and tricuspid aortic valve. Cardiol Res Pract 2012; 2012: 165957
33. Buchwalow IB, Podzuweit T, Samoilova VE, et al. An in situ evidence for autocrine function of NO in the vasculature. Nitric Oxide 2004; 10: 203-12
34. Galán M, Kassan M, Choi SK, et al. A novel role for epidermal growth factor receptor tyrosine kinase and its downstream endoplasmic reticulum stress in cardiac damage and microvascular dysfunction in type 1 diabetes mellitus. Hypertension 2012; 60: 71-80
35. El-Hashim AZ, Renno WM, Raghupathy R, et al. Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-B-dependent pathways. Br J Pharmacol 2012; 166: 1964-76
36. Rivas MA, Tkach M, Beguelin W, et al. Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation. Breast Cancer Res Treat 2010; 122: 111-24
37. Kassan M, Choi SK, Galán M, et al. Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice. Diabetes Metab Res Rev 2015; 31: 39-49
38. Gerondakis S, Fulford TS, Messina NL, Grumont RJ. NF-B control of T cell development. Nat Immunol 2014; 15: 15-25
39. Hoesel B, Schmid JA. The complexity of NF-B signaling in inflammation and cancer. Mol Cancer 2013; 12: 86. doi: 10.1186/1476-4598-12-86
40. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 2007; 112: 375-84
41. Li H, Telemaque S, Miller RE, Marsh JD. High glucose inhibits apoptosis induced by serum deprivation in vascular smooth muscle cells via upregulation of Bcl-2 and Bcl-xl. Diabetes 2005; 54: 540-5
42. Hall JL, Matter CM, Wang X, Gibbons GH. Hyperglycemia inhibits vascular smooth muscle cell apoptosis through a protein kinase C-dependent pathway. Circ Res 2000; 87: 574-80
43. Martínez-Hervás S, Vinué A, Núñez L, et al. Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis. Cardiovasc Res 2014; 103: 324-36
44. Wang P, Xu TY, Guan YF, et al. Vascular smooth muscle cell apoptosis is an early trigger for hypothyroid atherosclerosis. Cardiovasc Res 2014; 102: 448-59
45. Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. Angiotensin II and vascular injury. Curr Hypertens Rep 2014; 16: 431. doi: 10.1007/s11906-014-0431-2
46. Fiorentino TV, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des 2013; 19: 5695-703